Prevalence of Polycystic Ovary Syndrome among Malaysian Female University Staff

Document Type: Original Research Article

Authors

1 Department of Community Health, Faculty of Medicine and Health Sciences, University Putra Malaysia, Selangor, Malaysia

2 Professor, Department of Community Health, Faculty of Medicine and Health Sciences, University Putra Malaysia, Selangor, Malaysia

3 Fellow, Reproductive Medicine and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine and Health Sciences, University Putra Malaysia, Selangor, Malaysia

4 Senior Medical Lecturer, Department of Imaging, Faculty of Medicine and Health Sciences, University Putra Malaysia, Selangor, Malaysia

5 Professor, Department of Professional Development and Continuing Education, Faculty of Educational Studies, University Putra Malaysia, Selangor, Malaysia

6 Medical doctor, Department of Community Health, Faculty of Medicine and Health Sciences, University Putra Malaysia, Selangor, Malaysia

Abstract

Background & aim: Polycystic ovary syndrome (PCOS) is a metabolic disease with diverse etiologies. The prevalence of PCOS varies among different ethnicities and across various geographical and social settings. Scarce data exist on the prevalence of PCOS in Asia, especially in Malaysia. Regarding this, the present study was conducted to assess the prevalence of PCOS and its subtypes among the Malaysian University staff.
Methods: This cross-sectional study was performed on females of reproductive age working at University Putra Malaysia, Selangor, Malaysia. The study population was selected through simple random sampling technique. The women with thyroid abnormalities or adrenal hyperplasia were excluded
from the study. The participants were screened based on anthropometric measurements, medical history, blood pressure, and pelvic examination, as well as the presence of hirsutism, acne, and alopecia. The participants were also assessed for total and free testosterone levels and subjected to ultrasonography. The PCOS diagnosis was based on Rotterdam criteria. The data were analyzed using Mann-Whitney U test, t-test, Chi-square test, and logistic regression at the significance level of 0.05.
Results: A total of 675 females with the mean age of 26.01±7.14 years participated in this study. The prevalence rate of PCOS was obtained as 12.6%. All PCOS subjects were detected with hyperandrogenism and polycystic ovary, while anovulation was present in only one participant (1.2%). Odds of PCOS diagnosis was significantly related to increased body mass index (OR=1.14, 95% CI: 1.05-1.25), higher waist circumference (OR=1.06, 95% CI: 1.01-1.11), hirsutism (OR=20.83, 95% CI: 5.35- 81.13), and amenorrhea (OR=0.18, 95% CI: 0.04-0.69).
Conclusion: This study revealed a high prevalence of PCOS and a specific phenotype of PCOS among the Malaysian employees.

Keywords

Main Subjects


  1. Qiao J, Feng HL. Extra-and intra-ovarian factors in polycystic ovary syndrome: impact on
    oocyte maturation and embryo developmental competence. Human Reproduction Update. 2011; 17(1):17-33.
  2. Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocrine Reviews. 2015; 36(5):487-525.
  3. Walters KA. Androgens in polycystic ovary syndrome: lessons from experimental models. Current Opinion in Endocrinology, Diabetes, and Obesity. 2016; 23(3):257-263.
  4. Hart P, Eaton L, Buckner M, Morrow BN, Barrett DT, Fraser DD, et al. Effectiveness of a computer-based educational program on nurses’ knowledge, attitude, and skill level related to evidence-based practice. Worldviews on Evidence-Based Nursing. 2008; 5(2):75-84.
  5. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism. 2005; 90(4):1929-1935.
  6. Meyer C, McGrath BP, Teede HJ. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. Journal of Clinical Endocrinology Metabolism. 2005; 90(10):5711-5716.
  7. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Human Reproduction Update. 2006; 12(6):673-683.
  8. Jones GL, Hall JM, Balen AH, Ledger WL. Health-related quality of life measurement in women with polycystic ovary syndrome: a systematic review. Human Reproduction Update. 2008; 14(1):15-25.
  9. Okoroh EM, Hooper WC, Atrash HK, Yusuf HR, Boulet SL. Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States, 2003-2008. American Journal of Obstetrics and Gynecology. 2012; 207(5):377-e1-8.
  10. Bird ST, Hartzema AG, Brophy JM, Etminan M, Delaney JA. Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. Canadian Medical Association Journal. 2013; 185(2):E115-E120.
  11. Dashti S, Latiff LA, Hamid HA, Sani SM, Akhtari-Zavare M, Abu Bakar AS, et al. Sexual dysfunction in patients with polycystic ovary syndrome in malaysia. Asian Pacific Journal of Cancer Prevention. 2016; 17(8):3747-3751.
  12. Dashti S, Latiff LA, Zulkefli NA, Baharom AB, Minhat HS, Hamid HA, et al. A review on the assessment of the efficacy of common treatments in polycystic ovarian syndrome on prevention of diabetes mellitus. Journal of Family and Reproductive Health. 2017; 11(2):56-66.
  13. Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected caucasian women
    from Spain. Journal of Clinical Endocrinology Metabolism. 2000; 85(7):2434-2438.
  14. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Human Reproduction. 2010; 25(2):544-551.
  15. Franks S. Polycystic ovary syndrome. New England Journal of Medicine. 1995; 333(13):853-861.
  16. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility. 2004; 81(1):19-25.
  17. Johnson T, Kaplan L, Ouyang P, Rizza R. National Institutes of Health evidence-based methodology workshop on polycystic ovary syndrome (PCOS). NIH EbMW Report. Bethesda National Institute of Health. 2012; 1:1-14.
  18. Carmina E, Napoli N, Longo RA, Rini GB, Lobo RA. Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. European Journal of Endocrinology. 2006; 154(1):141-145.
  19. Wang L. China national nutrition and health survey 2002. Beijing: People’s Medical Publishing House; 2005.
  20. Rumball JS, Lebrun CM. Use of the preparticipation physical examination form to screen for the female athlete triad in Canadian interuniversity sport universities. Clinical Journal of Sport Medicine. 2005; 15(5):320-325.
  21. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. Journal of Clinical Endocrinology and Metabolism. 1961; 21(11):
    1440-1447.
  22. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. American Journal of Obstetrics Gynecology. 1981; 140(7):815-830.
  23. Ichikawa Y, Asai M, Masahashi T, Wu MC, Ohsawa M, Narita O, et al. Clinical assessment of body hair growth in Japanese women. The relationship between a grade of hirsutism and the menstrual status. Nihon Sanka Fujinka Gakkai Zasshi. 1988; 40(11):1719-1724.
  24. Reingold SB, Rosenfield RL. The relationship of mild hirsutism or acne in women to androgens. Archives of Dermatology. 1987; 123(2):209-212.
  25. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. Lancet. 2005; 366(9491):1059-1062.
  26. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clinical Epidemiology. 2013; 6:1-13.
  27. Li R, Zhang Q, Yang D, Li S, Lu S, Wu X, et al. Prevalence of polycystic ovary syndrome in women in China: a large community-based study. Human Reproduction. 2013; 28(9):2562-2569.
  28. Kumarapeli V, Seneviratne Rde A, Wijeyaratne CN, Yapa RM, Dodampahala SH. A simple screening approach for assessing community prevalence and phenotype of polycystic ovary syndrome in a semi-urban population in Sri Lanka. American Journal of Epidemiology. 2008; 168(3):321-328.
  29. Rodin DA, Bano G, Bland JM, Taylor K, Nussey SS. Polycystic ovaries and associated metabolic abnormalities in Indian subcontinent Asian women. Clinical Endocrinology. 1998; 49(1):91-99.
  30. Wijeyaratne CN, Balen AH, Belchetz PE. Polycystic ovary syndrome and its relevance to women
    from south Asia. Ceylon Medical Journal. 2002; 47(1):22-26.
  31. Nidhi R, Padmalatha V, Nagarathna R, Amritanshu R. Prevalence of polycystic ovarian syndrome in Indian adolescents. Journal of Pediatric and Adolescent Gynecology. 2011; 24(4):223-227.
  32. Chen X, Yang D, Mo Y, Li L, Chen Y, Huang Y. Prevalence of polycystic ovary syndrome in unselected women from southern China. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2008; 139(1):59-64.
  33. Wang S, Alvero R. Racial and ethnic differences in physiology and clinical symptoms of polycystic ovary syndrome. Seminars in Reproductive Medicine. 2013; 31(5):365-369.
  34. Lauritsen MP, Bentzen JG, Pinborg A, Loft A, Forman JL, Thuesen LL, et al. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Müllerian hormone. Human Reproduction. 2014; 29(4):791-801.
  35. Huang Z, Yong EL. Ethnic differences: is there
    an Asian phenotype for polycystic ovarian syndrome? Best practice & research. Clinical Obstetrics & Gynaecology. 2016; 37:46-55.
  36. Miyoshi A, Nagai S, Takeda M, Kondo T, Nomoto H, Kameda H, et al. Ovarian morphology and prevalence of polycystic ovary syndrome in Japanese women with type 1 diabetes mellitus. Journal of Diabetes Investigation. 2013; 4(3):
    326-329.
  37. Palomba S, Falbo A, Zullo F, Orio F Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocrine Reviews. 2009; 30(1):1-50.
  38. Jones GL, Palep-Singh M, Ledger WL, Balen AH, Jenkinson C, Campbell MJ, et al. Do South Asian women with PCOS have poorer health-related quality of life than Caucasian women with PCOS? A comparative cross-sectional study. Health and Quality of Life Outcomes. 2010; 8:149.
  39. Mani H, Davies MJ, Bodicoat DH, Levy MJ, Gray
    LJ, Howlett TA, et al. Clinical characteristics
    of polycystic ovary syndrome: investigating differences in white and south Asian women. Clinical Endocrinology. 2015; 83(4):542-549.
  40. Mehta J, Kamdar V, Dumesic D. Phenotypic expression of polycystic ovary syndrome in south Asian women. Obstetrical and Gynecological Survey. 2013; 68(3):228-234.
  41. Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A, et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. European Journal of Endocrinology. 2014; 171(4):P1-P29.